Clinical Trial Update: Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/II trial evaluating lenalidomide plus pembrolizumab in relapsed or refractory solid tumors with expansion to non-small cell lung cancer; study terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Or Refractory Solid Tumors

Drugs mentioned

• Lenalidomide (lenalidomide)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Relapsed or Refractory Solid Tumors, Nonsmall Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-12-30